These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 28254869)

  • 1. Phase II Study of a Radiotherapy Total Dose Increase in Hypoxic Lesions Identified by
    Vera P; Thureau S; Chaumet-Riffaud P; Modzelewski R; Bohn P; Vermandel M; Hapdey S; Pallardy A; Mahé MA; Lacombe M; Boisselier P; Guillemard S; Olivier P; Beckendorf V; Salem N; Charrier N; Chajon E; Devillers A; Aide N; Danhier S; Denis F; Muratet JP; Martin E; Riedinger AB; Kolesnikov-Gauthier H; Dansin E; Massabeau C; Courbon F; Farcy Jacquet MP; Kotzki PO; Houzard C; Mornex F; Vervueren L; Paumier A; Fernandez P; Salaun M; Dubray B
    J Nucl Med; 2017 Jul; 58(7):1045-1053. PubMed ID: 28254869
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radiotherapy boost in patients with hypoxic lesions identified by
    Vera P; Mihailescu SD; Lequesne J; Modzelewski R; Bohn P; Hapdey S; Pépin LF; Dubray B; Chaumet-Riffaud P; Decazes P; Thureau S;
    Eur J Nucl Med Mol Imaging; 2019 Jul; 46(7):1448-1456. PubMed ID: 30868230
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FDG and FMISO PET-guided dose escalation with intensity-modulated radiotherapy in lung cancer.
    Thureau S; Dubray B; Modzelewski R; Bohn P; Hapdey S; Vincent S; Anger E; Gensanne D; Pirault N; Pierrick G; Vera P
    Radiat Oncol; 2018 Oct; 13(1):208. PubMed ID: 30352608
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of Hypermetabolic and Hypoxic Volumes Delineated on [
    Thureau S; Modzelewski R; Bohn P; Hapdey S; Gouel P; Dubray B; Vera P
    Mol Imaging Biol; 2020 Jun; 22(3):764-771. PubMed ID: 31432388
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interobserver agreement of qualitative analysis and tumor delineation of 18F-fluoromisonidazole and 3'-deoxy-3'-18F-fluorothymidine PET images in lung cancer.
    Thureau S; Chaumet-Riffaud P; Modzelewski R; Fernandez P; Tessonnier L; Vervueren L; Cachin F; Berriolo-Riedinger A; Olivier P; Kolesnikov-Gauthier H; Blagosklonov O; Bridji B; Devillers A; Collombier L; Courbon F; Gremillet E; Houzard C; Caignon JM; Roux J; Aide N; Brenot-Rossi I; Doyeux K; Dubray B; Vera P
    J Nucl Med; 2013 Sep; 54(9):1543-50. PubMed ID: 23918733
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lack of correlation of hypoxic cell fraction and angiogenesis with glucose metabolic rate in non-small cell lung cancer assessed by 18F-Fluoromisonidazole and 18F-FDG PET.
    Cherk MH; Foo SS; Poon AM; Knight SR; Murone C; Papenfuss AT; Sachinidis JI; Saunder TH; O'Keefe GJ; Scott AM
    J Nucl Med; 2006 Dec; 47(12):1921-6. PubMed ID: 17138734
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Simultaneous positron emission tomography (PET) assessment of metabolism with ¹⁸F-fluoro-2-deoxy-d-glucose (FDG), proliferation with ¹⁸F-fluoro-thymidine (FLT), and hypoxia with ¹⁸fluoro-misonidazole (F-miso) before and during radiotherapy in patients with non-small-cell lung cancer (NSCLC): a pilot study.
    Vera P; Bohn P; Edet-Sanson A; Salles A; Hapdey S; Gardin I; Ménard JF; Modzelewski R; Thiberville L; Dubray B
    Radiother Oncol; 2011 Jan; 98(1):109-16. PubMed ID: 21056487
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic Analysis of Dynamic
    Schwartz J; Grkovski M; Rimner A; Schöder H; Zanzonico PB; Carlin SD; Staton KD; Humm JL; Nehmeh SA
    J Nucl Med; 2017 Jun; 58(6):911-919. PubMed ID: 28232611
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic impact of hypoxia imaging with 18F-misonidazole PET in non-small cell lung cancer and head and neck cancer before radiotherapy.
    Eschmann SM; Paulsen F; Reimold M; Dittmann H; Welz S; Reischl G; Machulla HJ; Bares R
    J Nucl Med; 2005 Feb; 46(2):253-60. PubMed ID: 15695784
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The reoxygenation of hypoxia and the reduction of glucose metabolism in head and neck cancer by fractionated radiotherapy with intensity-modulated radiation therapy.
    Okamoto S; Shiga T; Yasuda K; Watanabe S; Hirata K; Nishijima KI; Magota K; Kasai K; Onimaru R; Tuchiya K; Kuge Y; Shirato H; Tamaki N
    Eur J Nucl Med Mol Imaging; 2016 Nov; 43(12):2147-2154. PubMed ID: 27251644
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dosimetry study of
    Li H; Xu D; Han X; Ruan Q; Zhang X; Mi Y; Dong M; Guo S; Lin Y; Wang B; Li G
    Clin Transl Oncol; 2018 Oct; 20(10):1329-1336. PubMed ID: 29623584
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Buparlisib with thoracic radiotherapy and its effect on tumour hypoxia: A phase I study in patients with advanced non-small cell lung carcinoma.
    McGowan DR; Skwarski M; Bradley KM; Campo L; Fenwick JD; Gleeson FV; Green M; Horne A; Maughan TS; McCole MG; Mohammed S; Muschel RJ; Ng SM; Panakis N; Prevo R; Strauss VY; Stuart R; Tacconi EMC; Vallis KA; McKenna WG; Macpherson RE; Higgins GS
    Eur J Cancer; 2019 May; 113():87-95. PubMed ID: 30991262
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [18F] fluoromisonidazole and [18F] fluorodeoxyglucose positron emission tomography in response evaluation after chemo-/radiotherapy of non-small-cell lung cancer: a feasibility study.
    Gagel B; Reinartz P; Demirel C; Kaiser HJ; Zimny M; Piroth M; Pinkawa M; Stanzel S; Asadpour B; Hamacher K; Coenen HH; Buell U; Eble MJ
    BMC Cancer; 2006 Mar; 6():51. PubMed ID: 16515707
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radiosensitizing effect of irisquinone on glioma through the downregulation of HIF-1α evaluated by 18F-FDG and 18F-FMISO PET/CT.
    Wang H; Zhang Y; Yu W; Zhao X; Xue Y; Xu H
    Nucl Med Commun; 2016 Jul; 37(7):705-14. PubMed ID: 26963468
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multimodal hypoxia imaging and intensity modulated radiation therapy for unresectable non-small-cell lung cancer: the HIL trial.
    Askoxylakis V; Dinkel J; Eichinger M; Stieltjes B; Sommer G; Strauss LG; Dimitrakopoulou-Strauss A; Kopp-Schneider A; Haberkorn U; Huber PE; Bischof M; Debus J; Thieke C
    Radiat Oncol; 2012 Sep; 7():157. PubMed ID: 22974533
    [TBL] [Abstract][Full Text] [Related]  

  • 16. To Explore a Representative Hypoxic Parameter to Predict the Treatment Response and Prognosis Obtained by [
    Li L; Wei Y; Huang Y; Yu Q; Liu W; Zhao S; Zheng J; Lu H; Yu J; Yuan S
    Mol Imaging Biol; 2018 Dec; 20(6):1061-1067. PubMed ID: 29623510
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of SBRT fractionation in hypoxia dose painting - Accounting for heterogeneous and dynamic tumor oxygenation.
    Kjellsson Lindblom E; Ureba A; Dasu A; Wersäll P; Even AJG; van Elmpt W; Lambin P; Toma-Dasu I
    Med Phys; 2019 May; 46(5):2512-2521. PubMed ID: 30924937
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fluorine-18-labeled fluoromisonidazole positron emission and computed tomography-guided intensity-modulated radiotherapy for head and neck cancer: a feasibility study.
    Lee NY; Mechalakos JG; Nehmeh S; Lin Z; Squire OD; Cai S; Chan K; Zanzonico PB; Greco C; Ling CC; Humm JL; Schöder H
    Int J Radiat Oncol Biol Phys; 2008 Jan; 70(1):2-13. PubMed ID: 17869020
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Using positron emission tomography (PET) response criteria in solid tumours (PERCIST) 1.0 for evaluation of 2'-deoxy-2'-[18F] fluoro-D-glucose-PET/CT scans to predict survival early during treatment of locally advanced non-small cell lung cancer (NSCLC).
    Fledelius J; Khalil AA; Hjorthaug K; Frøkiaer J
    J Med Imaging Radiat Oncol; 2016 Apr; 60(2):231-8. PubMed ID: 26678718
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor Hypoxia Response After Targeted Therapy in EGFR-Mutant Non-Small Cell Lung Cancer: Proof of Concept for FMISO-PET.
    Arvold ND; Heidari P; Kunawudhi A; Sequist LV; Mahmood U
    Technol Cancer Res Treat; 2016 Apr; 15(2):234-42. PubMed ID: 25759424
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.